N-炔丙基甘氨酸通过预防草酸钙结石形成、肾小管损伤和肾功能障碍,在致死性2型原发性高草酸尿症小鼠模型中恢复生存
本研究在Grhpr敲除小鼠(2型原发性高草酸尿症模型)中评估N-炔丙基甘氨酸(N-PPG)的临床前疗效。口服N-PPG三周内显著降低高草酸尿症和体重下降,并预防草酸钙结石形成和肾小管损伤;在24周生存研究中,N-PPG使Grhpr敲除小鼠的体重和生存率完全恢复至野生型对照水平,并持续抑制高草酸尿症、预防结石形成、肾小管损伤和肾功能丧失。
要点
- N-PPG可显著降低Grhpr敲除小鼠的高草酸尿症和体重下降。
- N-PPG预防草酸钙结石形成和肾小管损伤。
- N-PPG使Grhpr敲除小鼠的生存率恢复至野生型水平。
核心结论
- N-PPG是长期预防PH2中草酸钙结石形成和肾衰竭并发症的有前景的治疗候选药物。
研究设计与样本
- 使用Grhpr敲除小鼠(PH2模型)评估N-PPG的临床前疗效,测量草酸盐水平、草酸钙结石形成、胱抑素C水平、白蛋白/肌酐比值、肾小管损伤标志物、代谢物、体重和寿命。
主要发现
- 口服N-PPG三周内显著降低Grhpr敲除小鼠的高草酸尿症和体重下降,并预防草酸钙结石形成和肾小管损伤。
- 在24周生存研究中,载体处理的Grhpr敲除小鼠中位生存期仅15周,而每日N-PPG治疗使体重和生存率完全恢复至野生型对照水平。
- N-PPG在延长治疗期间抑制高草酸尿症,预防草酸钙结石形成、肾小管损伤和肾功能丧失,效果与对照相当。
临床怎么用
- N-PPG可能作为PH2患者长期预防草酸钙结石和肾衰竭的潜在疗法,但需进一步临床验证。
局限性
- 研究仅基于小鼠模型,结果尚未在人体中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: New therapeutics are needed to address the rapid progression of calcium oxalate (CaOx) nephrolithiasis and life-threatening kidney failure afflicting infants and young adults with one of the three different genetic types of Primary Hyperoxaluria (PH) types 1, 2, and 3. Glyoxylate and hydroxypyruvate reductase knockout (Grhpr KO) mice recapitulate the pathophysiology of PH type 2 (PH2), developing accelerated hyperoxaluria and CaOx kidney stone formation. Previous studies have shown that this process can be mitigated by introducing an additional genetic knockout of the liver and kidney mitochondrial enzyme, hydroxyproline dehydrogenase (Hypdh/Prodh2), which is responsible for the first step in liver production of glyoxylate and oxalate. METHODS: Using Grhpr KO mice, we evaluated N-propargylglycine (N-PPG) as a preclinical candidate for PH2, measuring oxalate levels, CaOx stone formation, Cystatin C levels, albumin/creatinine ratio, kidney tubule damage by kidney injury molecule-1 and Lotus Tetragonolobus lectin immunohistochemistry, metabolites, weight, and lifespan. RESULTS: Oral administration of N-PPG, a well-tolerated small-molecule inhibitor of Hypdh/Prodh2, significantly reduces hyperoxaluria and weight loss in Grhpr KO mice within three weeks, while preventing CaOx stone formation and kidney tubular damage. In a 24-week survival study during which vehicle-treated Grhpr KO mice exhibit a median survival of only 15 weeks, daily treatment with N-PPG fully restores weight and survival in the Grhpr KO mice to that of wild-type control mice. N-PPG suppressed hyperoxaluria during this extended treatment period, preventing CaOx stone formation, kidney tubule injury and loss of kidney function, achieving beneficial outcomes in this PH2 mouse model comparable to controls. CONCLUSIONS: Our findings establish N-PPG as a promising therapeutic candidate for the long-term prevention of CaOx kidney stone formation and kidney failure complications in PH2.
引用
- Hady M, Tadeo A, Stoyanova D, et al. N-propargylglycine restores survival by preventing calcium oxalate stone formation, tubular injury, and kidney dysfunction in a lethal mouse model of primary hyperoxaluria type 2. Kidney Int. 2026. PMID: 41866121. doi:10.1016/j.kint.2026.02.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。